Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) has received an average recommendation of "Buy" from the eleven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $16.5556.
Several equities research analysts have commented on IVA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald began coverage on Inventiva in a research report on Friday, July 17th. They issued an "overweight" rating on the stock.
Read Our Latest Stock Report on IVA
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Creative Planning acquired a new stake in Inventiva during the 2nd quarter worth $32,000. Virtu Financial LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at about $60,000. XTX Topco Ltd purchased a new position in shares of Inventiva in the fourth quarter worth about $84,000. Cerity Partners LLC purchased a new position in shares of Inventiva in the fourth quarter worth about $93,000. Finally, NewEdge Advisors LLC acquired a new position in Inventiva during the third quarter worth about $116,000. 19.06% of the stock is owned by institutional investors and hedge funds.
Inventiva Stock Performance
IVA opened at $4.72 on Wednesday. Inventiva has a twelve month low of $3.35 and a twelve month high of $7.98. The company has a 50-day moving average price of $4.15 and a 200 day moving average price of $5.22.
Inventiva Company Profile
(
Get Free Report)
Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
